CHICAGO, March 22, 2019 /PRNewswire-PRWeb/ -- CancerIQ, a cancer risk assessment and management company, and AliveAndKickn,
"We are excited to partner with AliveAndKickn because they share our passion for predicting, preempting and preventing hereditary cancer," said Haibo Lu, co-founder and VP of Product and Customer Success, CancerIQ. "Their wealth of resources will help providers who use the CancerIQ platform to identify more patients with Lynch Syndrome and reduce their risk."
Lynch syndrome is an inherited genetic condition that increases a person's risk of certain cancers, most common of which are colorectal and endometrial cancers. Patients who test Lynch-positive are also at risk for developing related cancers at much earlier ages than the general population. Unfortunately, awareness is staggeringly low. Research shows that approximately one in 297 individuals are Lynch positive, yet 95 percent are unaware that they possess the genetic mutation.
"So many patients are in the dark about Lynch Syndrome," said Robin Dubin, co-founder and Executive Director, AliveAndKickn. "We are partnering with CancerIQ to change that. Through their technology and hospital partnerships, we are able to dramatically expand the reach of our educational and support resources, and arm far more patients—and their family members—to take preventive measures before they receive a cancer diagnosis."
Per the agreement, AliveandKickn's content will be integrated into CancerIQ in several ways beginning in May. If a patient is flagged as meeting high risk criteria for Lynch Syndrome, educational information explaining the importance of genetic testing—and what it entails—will be provided through follow-up email reminders.
"This collaboration aligns with our overall strategy to be the premier source of content for both patients and providers who are trying to address the burden of hereditary disease," said Feyi Olopade Ayodele, co-founder and CEO of CancerIQ.
Those diagnosed with Lynch Syndrome will routinely receive information around both near- and long-term patient management and support options. They will also be prompted to enroll in the HEROIC Registry, which will enable patients to play an active role in the research process and the sharing of insights, experiences and valuable health information about Lynch Syndrome that can help lead to new discoveries.
As a result of the partnership, both companies will be better able to help both providers and patients take preventative measures against hereditary cancer.
CancerIQ's technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at Canceriq.com.
AliveAndKickn's mission is to improve the lives of individuals and families affected by Lynch Syndrome and associated cancers through research, education, and screening. AliveAndKickn, founded by David and Robin Dubin in 2012, has quickly become a nationally recognized organization to provide resources, education and awareness for individuals with Lynch syndrome hereditary cancer mutations through innovative resources like the HEROIC Patient Registry, national partnerships with other advocacy organization and partnering on research studies with academic institutions. To read more about AliveAndKickn, please visit http://www.AliveAndKickn.org.
Subscribe to our Free Newsletters!